Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension
The effect of antihypertensive drugs on lipoprotein subfraction profile is still under investigation. In this study the effects of fixed combination of valsartan with either amlodipine (V–A) or hydrochlorothiazide (V–H) on low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) subfraction...
Gespeichert in:
| Veröffentlicht in: | Journal of human hypertension 2013-01, Vol.27 (1), p.44-50 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 50 |
|---|---|
| container_issue | 1 |
| container_start_page | 44 |
| container_title | Journal of human hypertension |
| container_volume | 27 |
| creator | Christogiannis, L G Kostapanos, M S Tellis, C C Milionis, H J Tselepis, A D Elisaf, M S |
| description | The effect of antihypertensive drugs on lipoprotein subfraction profile is still under investigation. In this study the effects of fixed combination of valsartan with either amlodipine (V–A) or hydrochlorothiazide (V–H) on low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) subfraction profile of patients with stage 2 or 3 hypertension were assessed. A total of 60 drug-naive patients were randomized to either V–A (160/5 mg,
n
=30) or V–H (160/12.5 mg,
n
=30). At baseline as well as 16 weeks post-treatment analysis of the LDL and HDL subfraction profile was conducted by using LDL Lipoprint System. Both V–A and V–H effectively reduced blood pressure (BP) to similar levels. An increase in the cholesterol concentration of small-dense LDL subfractions (by 18.2%,
P |
| doi_str_mv | 10.1038/jhh.2011.108 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1223432933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2832007941</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-d68b28f823614724ae1eddc750eb57885a8caad496b79cf9bfce183cc5c2e993</originalsourceid><addsrcrecordid>eNptkU9vFSEUxYmxsc_qzrUhcePCqcD8g6WprTZp4qb7CcNcHF5mYARGfX4cP6l3-qoxTTcQzv3lnEsOIa84O-eslO_343guGOf4kk_IjldtU9S1aJ-SHVM1K5So2Cl5ntKesW0on5FTIbhQDWt35PdHl7LzJlOwFkxONFhq3U8YqAlz77zOLvg79bueko5Ze_rD5ZECHhCpnqcwuMV5oCHS8TDEYMYpxJBHp3-5AWVPJ7eEBSVwnqa1t1GbzZaiZt0EFOUFg8Bj_p35eFggZvAJqRfkxGI0vLy_z8jt1eXtxefi5sun64sPN4UpVZ2LoZG9kFaKssFvikoDh2Ewbc2gr1spay2N1kOlmr5VxqreGuCyNKY2ApQqz8jboy0u9W2FlLvZJQPTpD2ENXVciLIqhSpLRN88QPdhjR6X2yguW6XqzfDdkTIxpBTBdkt0s46HjrNuq67D6rqtOnxJxF_fm679DMM_-G9XCBRHIOHIf4X4X-pjhn8A_5Coqg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1221879959</pqid></control><display><type>article</type><title>Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Christogiannis, L G ; Kostapanos, M S ; Tellis, C C ; Milionis, H J ; Tselepis, A D ; Elisaf, M S</creator><creatorcontrib>Christogiannis, L G ; Kostapanos, M S ; Tellis, C C ; Milionis, H J ; Tselepis, A D ; Elisaf, M S</creatorcontrib><description>The effect of antihypertensive drugs on lipoprotein subfraction profile is still under investigation. In this study the effects of fixed combination of valsartan with either amlodipine (V–A) or hydrochlorothiazide (V–H) on low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) subfraction profile of patients with stage 2 or 3 hypertension were assessed. A total of 60 drug-naive patients were randomized to either V–A (160/5 mg,
n
=30) or V–H (160/12.5 mg,
n
=30). At baseline as well as 16 weeks post-treatment analysis of the LDL and HDL subfraction profile was conducted by using LDL Lipoprint System. Both V–A and V–H effectively reduced blood pressure (BP) to similar levels. An increase in the cholesterol concentration of small-dense LDL subfractions (by 18.2%,
P
<0.05) was observed in the V–H group, whereas this parameter remained unchanged in the V–A group. Therefore, mean LDL particle size was decreased in the V–H group (from 267±5 to 266±5Å,
P
<0.05). HDL-Cholesterol (HDL-C) levels were reduced by 4.7% (
P
<0.05) in the V–H group, mirrored by a reduction in the cholesterol mass of small and intermediate HDL particles. In conclusion, despite similar reductions in BP, V–H combination may adversely affect serum lipids as well as LDL and HDL subfraction profile as compared with V–A.</description><identifier>ISSN: 0950-9240</identifier><identifier>EISSN: 1476-5527</identifier><identifier>DOI: 10.1038/jhh.2011.108</identifier><identifier>PMID: 22129607</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject><![CDATA[631/45/287/1191 ; 631/92/436/108 ; 692/699/75/243 ; Adult ; Aged ; Amlodipine - administration & dosage ; Amlodipine - adverse effects ; Antihypertensive Agents - administration & dosage ; Cholesterol - blood ; Epidemiology ; Female ; Health Administration ; Humans ; Hydrochlorothiazide - administration & dosage ; Hydrochlorothiazide - adverse effects ; Hypertension - blood ; Hypertension - drug therapy ; Lipoproteins, HDL - blood ; Lipoproteins, LDL - blood ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; original-article ; Particle Size ; Public Health ; Tetrazoles - administration & dosage ; Tetrazoles - adverse effects ; Triglycerides - blood ; Valine - administration & dosage ; Valine - adverse effects ; Valine - analogs & derivatives ; Valsartan]]></subject><ispartof>Journal of human hypertension, 2013-01, Vol.27 (1), p.44-50</ispartof><rights>Macmillan Publishers Limited 2013</rights><rights>Copyright Nature Publishing Group Jan 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-d68b28f823614724ae1eddc750eb57885a8caad496b79cf9bfce183cc5c2e993</citedby><cites>FETCH-LOGICAL-c395t-d68b28f823614724ae1eddc750eb57885a8caad496b79cf9bfce183cc5c2e993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/jhh.2011.108$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/jhh.2011.108$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22129607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Christogiannis, L G</creatorcontrib><creatorcontrib>Kostapanos, M S</creatorcontrib><creatorcontrib>Tellis, C C</creatorcontrib><creatorcontrib>Milionis, H J</creatorcontrib><creatorcontrib>Tselepis, A D</creatorcontrib><creatorcontrib>Elisaf, M S</creatorcontrib><title>Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension</title><title>Journal of human hypertension</title><addtitle>J Hum Hypertens</addtitle><addtitle>J Hum Hypertens</addtitle><description>The effect of antihypertensive drugs on lipoprotein subfraction profile is still under investigation. In this study the effects of fixed combination of valsartan with either amlodipine (V–A) or hydrochlorothiazide (V–H) on low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) subfraction profile of patients with stage 2 or 3 hypertension were assessed. A total of 60 drug-naive patients were randomized to either V–A (160/5 mg,
n
=30) or V–H (160/12.5 mg,
n
=30). At baseline as well as 16 weeks post-treatment analysis of the LDL and HDL subfraction profile was conducted by using LDL Lipoprint System. Both V–A and V–H effectively reduced blood pressure (BP) to similar levels. An increase in the cholesterol concentration of small-dense LDL subfractions (by 18.2%,
P
<0.05) was observed in the V–H group, whereas this parameter remained unchanged in the V–A group. Therefore, mean LDL particle size was decreased in the V–H group (from 267±5 to 266±5Å,
P
<0.05). HDL-Cholesterol (HDL-C) levels were reduced by 4.7% (
P
<0.05) in the V–H group, mirrored by a reduction in the cholesterol mass of small and intermediate HDL particles. In conclusion, despite similar reductions in BP, V–H combination may adversely affect serum lipids as well as LDL and HDL subfraction profile as compared with V–A.</description><subject>631/45/287/1191</subject><subject>631/92/436/108</subject><subject>692/699/75/243</subject><subject>Adult</subject><subject>Aged</subject><subject>Amlodipine - administration & dosage</subject><subject>Amlodipine - adverse effects</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Cholesterol - blood</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Health Administration</subject><subject>Humans</subject><subject>Hydrochlorothiazide - administration & dosage</subject><subject>Hydrochlorothiazide - adverse effects</subject><subject>Hypertension - blood</subject><subject>Hypertension - drug therapy</subject><subject>Lipoproteins, HDL - blood</subject><subject>Lipoproteins, LDL - blood</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>original-article</subject><subject>Particle Size</subject><subject>Public Health</subject><subject>Tetrazoles - administration & dosage</subject><subject>Tetrazoles - adverse effects</subject><subject>Triglycerides - blood</subject><subject>Valine - administration & dosage</subject><subject>Valine - adverse effects</subject><subject>Valine - analogs & derivatives</subject><subject>Valsartan</subject><issn>0950-9240</issn><issn>1476-5527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkU9vFSEUxYmxsc_qzrUhcePCqcD8g6WprTZp4qb7CcNcHF5mYARGfX4cP6l3-qoxTTcQzv3lnEsOIa84O-eslO_343guGOf4kk_IjldtU9S1aJ-SHVM1K5So2Cl5ntKesW0on5FTIbhQDWt35PdHl7LzJlOwFkxONFhq3U8YqAlz77zOLvg79bueko5Ze_rD5ZECHhCpnqcwuMV5oCHS8TDEYMYpxJBHp3-5AWVPJ7eEBSVwnqa1t1GbzZaiZt0EFOUFg8Bj_p35eFggZvAJqRfkxGI0vLy_z8jt1eXtxefi5sun64sPN4UpVZ2LoZG9kFaKssFvikoDh2Ewbc2gr1spay2N1kOlmr5VxqreGuCyNKY2ApQqz8jboy0u9W2FlLvZJQPTpD2ENXVciLIqhSpLRN88QPdhjR6X2yguW6XqzfDdkTIxpBTBdkt0s46HjrNuq67D6rqtOnxJxF_fm679DMM_-G9XCBRHIOHIf4X4X-pjhn8A_5Coqg</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Christogiannis, L G</creator><creator>Kostapanos, M S</creator><creator>Tellis, C C</creator><creator>Milionis, H J</creator><creator>Tselepis, A D</creator><creator>Elisaf, M S</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20130101</creationdate><title>Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension</title><author>Christogiannis, L G ; Kostapanos, M S ; Tellis, C C ; Milionis, H J ; Tselepis, A D ; Elisaf, M S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-d68b28f823614724ae1eddc750eb57885a8caad496b79cf9bfce183cc5c2e993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>631/45/287/1191</topic><topic>631/92/436/108</topic><topic>692/699/75/243</topic><topic>Adult</topic><topic>Aged</topic><topic>Amlodipine - administration & dosage</topic><topic>Amlodipine - adverse effects</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Cholesterol - blood</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Health Administration</topic><topic>Humans</topic><topic>Hydrochlorothiazide - administration & dosage</topic><topic>Hydrochlorothiazide - adverse effects</topic><topic>Hypertension - blood</topic><topic>Hypertension - drug therapy</topic><topic>Lipoproteins, HDL - blood</topic><topic>Lipoproteins, LDL - blood</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>original-article</topic><topic>Particle Size</topic><topic>Public Health</topic><topic>Tetrazoles - administration & dosage</topic><topic>Tetrazoles - adverse effects</topic><topic>Triglycerides - blood</topic><topic>Valine - administration & dosage</topic><topic>Valine - adverse effects</topic><topic>Valine - analogs & derivatives</topic><topic>Valsartan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Christogiannis, L G</creatorcontrib><creatorcontrib>Kostapanos, M S</creatorcontrib><creatorcontrib>Tellis, C C</creatorcontrib><creatorcontrib>Milionis, H J</creatorcontrib><creatorcontrib>Tselepis, A D</creatorcontrib><creatorcontrib>Elisaf, M S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of human hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Christogiannis, L G</au><au>Kostapanos, M S</au><au>Tellis, C C</au><au>Milionis, H J</au><au>Tselepis, A D</au><au>Elisaf, M S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension</atitle><jtitle>Journal of human hypertension</jtitle><stitle>J Hum Hypertens</stitle><addtitle>J Hum Hypertens</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>27</volume><issue>1</issue><spage>44</spage><epage>50</epage><pages>44-50</pages><issn>0950-9240</issn><eissn>1476-5527</eissn><abstract>The effect of antihypertensive drugs on lipoprotein subfraction profile is still under investigation. In this study the effects of fixed combination of valsartan with either amlodipine (V–A) or hydrochlorothiazide (V–H) on low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) subfraction profile of patients with stage 2 or 3 hypertension were assessed. A total of 60 drug-naive patients were randomized to either V–A (160/5 mg,
n
=30) or V–H (160/12.5 mg,
n
=30). At baseline as well as 16 weeks post-treatment analysis of the LDL and HDL subfraction profile was conducted by using LDL Lipoprint System. Both V–A and V–H effectively reduced blood pressure (BP) to similar levels. An increase in the cholesterol concentration of small-dense LDL subfractions (by 18.2%,
P
<0.05) was observed in the V–H group, whereas this parameter remained unchanged in the V–A group. Therefore, mean LDL particle size was decreased in the V–H group (from 267±5 to 266±5Å,
P
<0.05). HDL-Cholesterol (HDL-C) levels were reduced by 4.7% (
P
<0.05) in the V–H group, mirrored by a reduction in the cholesterol mass of small and intermediate HDL particles. In conclusion, despite similar reductions in BP, V–H combination may adversely affect serum lipids as well as LDL and HDL subfraction profile as compared with V–A.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>22129607</pmid><doi>10.1038/jhh.2011.108</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-9240 |
| ispartof | Journal of human hypertension, 2013-01, Vol.27 (1), p.44-50 |
| issn | 0950-9240 1476-5527 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1223432933 |
| source | MEDLINE; SpringerLink Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | 631/45/287/1191 631/92/436/108 692/699/75/243 Adult Aged Amlodipine - administration & dosage Amlodipine - adverse effects Antihypertensive Agents - administration & dosage Cholesterol - blood Epidemiology Female Health Administration Humans Hydrochlorothiazide - administration & dosage Hydrochlorothiazide - adverse effects Hypertension - blood Hypertension - drug therapy Lipoproteins, HDL - blood Lipoproteins, LDL - blood Male Medicine Medicine & Public Health Middle Aged original-article Particle Size Public Health Tetrazoles - administration & dosage Tetrazoles - adverse effects Triglycerides - blood Valine - administration & dosage Valine - adverse effects Valine - analogs & derivatives Valsartan |
| title | Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T01%3A50%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinct%20effects%20of%20fixed%20combinations%20of%20valsartan%20with%20either%20amlodipine%20or%20hydrochlorothiazide%20on%20lipoprotein%20subfraction%20profile%20in%20patients%20with%20hypertension&rft.jtitle=Journal%20of%20human%20hypertension&rft.au=Christogiannis,%20L%20G&rft.date=2013-01-01&rft.volume=27&rft.issue=1&rft.spage=44&rft.epage=50&rft.pages=44-50&rft.issn=0950-9240&rft.eissn=1476-5527&rft_id=info:doi/10.1038/jhh.2011.108&rft_dat=%3Cproquest_cross%3E2832007941%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1221879959&rft_id=info:pmid/22129607&rfr_iscdi=true |